Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889425 | 0.80 | CHRM2 (0.40) | LMNAALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL5520513 | 0.80 | TDP1 (0.47) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL24311998 | 0.78 | MAPT (0.34) | HSD17B10ALOX5MAPTPKM | |
| SCHEMBL18403759 | 0.78 | KDM4E (0.35) | LMNAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL28289835 | 0.78 | TDP1 (0.45) | ALDH1A1KDM4EHSD17B10HPGDPOLB | |
| SCHEMBL7140275 | 0.78 | ALDH1A1 (0.54) | LMNAALDH1A1KDM4EHSD17B10PRNP | |
| SCHEMBL29263881 | 0.78 | MAPT (0.45) | LMNAALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL28362770 | 0.77 | PTGER1 (0.38) | LMNAALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL3742201 | 0.76 | ALDH1A1 (0.52) | LMNAALDH1A1KDM4EHSD17B10PRNP | |
| SCHEMBL2303474 | 0.75 | MEN1 (0.58) | LMNAALDH1A1KDM4EHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11066398-B2 | Small molecule c-Myc inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| US-20160264560-A1 | SMALL MOLECULE C-MYC INHIBITORS | SORRENTO THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264560-A1 | SMALL MOLECULE C-MYC INHIBITORS | SORRENTO THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2012155066-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | WANG SHAOMENG (US) | 2012-11-15 | — | — | WO | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| WO-2010045009-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093702-A1 | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093702-A1 | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093702-A1 | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | LMNA 2478/4885ALDH1A1 1907/4885KDM4E 2256/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | LMNA 3309/4885ALDH1A1 3556/4885KDM4E 2322/4885 |
| US-20160264560-A1 | SMALL MOLECULE C-MYC INHIBITORS | MYC, MYCBP, MYCBP2 | LMNA 3226/4885ALDH1A1 3976/4885KDM4E 931/4885 |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | LMNA 4010/4885ALDH1A1 1246/4885KDM4E 3165/4885 |
| US-11066398-B2 | Small molecule c-Myc inhibitors | MYC, MYCBP, MYCBP2 | LMNA 3226/4885ALDH1A1 3976/4885KDM4E 931/4885 |
| US-20100093702-A1 | METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | LMNA 3936/4885ALDH1A1 490/4885KDM4E 2403/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | LMNA 2854/4885ALDH1A1 2980/4885KDM4E 2079/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | LMNA 2524/4885ALDH1A1 1875/4885KDM4E 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.